









Markets
/
Stocks
/
nasdaq-bglc
/

BioNexus Gene Lab Corp

BGLC

2.110USD

+0.120+6.03%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.79MMarket Cap

LossP/E TTM



BioNexus Gene Lab Corp

2.110

+0.120+6.03%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BioNexus Gene Lab Corp

Currency: USD Updated: 2026-02-06

Key Insights

BioNexus Gene Lab Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 204 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioNexus Gene Lab Corp's Score

Industry at a Glance

Industry Ranking

204 / 392

Overall Ranking

398 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

BioNexus Gene Lab Corp Highlights

StrengthsRisks

BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.51M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 9.51M.

Overvalued

The company’s latest PE is -1.65, at a high 3-year percentile range.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.96.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of BioNexus Gene Lab Corp is 8.07, ranking 63 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.54M, representing a year-over-year decrease of 3.29%, while its net profit experienced a year-over-year decrease of 47.30%.

Score

Industry at a Glance

Previous score

8.07

Change



Financials

7.98

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.63

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

BioNexus Gene Lab Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of BioNexus Gene Lab Corp is 8.82, ranking 15 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.65, which is -5.69% below the recent high of -1.56 and -9169.23% above the recent low of -153.03.

Score

Industry at a Glance

Previous score

8.82

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 204/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for BioNexus Gene Lab Corp. The Biotechnology & Medical Research industry's average is 8.05.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of BioNexus Gene Lab Corp is 5.07, ranking 334 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.41 and the support level at 1.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.00

Change

0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.150

Sell

RSI(14)

23.944

Sell

STOCH(KDJ)(9,3,3)

8.481

Oversold

ATR(14)

0.317

Low Volatility

CCI(14)

-143.783

Sell

Williams %R

92.653

Oversold

TRIX(12,20)

-1.862

Sell

StochRSI(14)

40.595

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.385

Sell

MA10

2.573

Sell

MA20

3.049

Sell

MA50

3.726

Sell

MA100

4.462

Sell

MA200

4.405

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelion Diagnostics Pte Ltd

392.33K

ARC Group Ltd

175.00K

Liew (Choong-Chin)

166.67K

-0.00%

Lai (Soo Kow(kenny))

125.00K

-0.00%

DRW Securities, LLC

14.65K

Geode Capital Management, L.L.C.

-100.00%

Low (Jook Yuen)

1.26K

-0.08%

Blackstone Alternative Investment Advisors LLC

3.00

Scientech Research LLC

-100.00%

XTX Markets LLC

-100.00%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioNexus Gene Lab Corp is 2.70, ranking 210 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.32. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.